secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-06-04T12:00:53+00:00
Accession:  0001104659-26-070345
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis
--------------------------------------------------------------------------------

- Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.
- SHIMMER Phase 2: 86% slowing of NPI-12 decline vs placebo; 89% slowing of hallucinations/delusions.
- FDA Division of Psychiatry meeting held May 20, 2026; minutes expected June 2026; registrational study design being finalized.
- Registrational plan: 9-month, 1:1 zervimesine 100mg vs placebo, endpoint NPI-2; open-label extension planned.
- START Phase 2 in early Alzheimer's (545 pts) ongoing; topline data expected 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926070345/0001104659-26-070345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926070345/tm2616896d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-070345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer